Erazaban, 10% cream 2 g

Indications

Skin infections caused by Herpes simplex virus type 1 (including lip herpes) in immunocompetent patients.

Active ingredient

Composition

1 g of cream for external use contains:

the active ingredient:

docosanol 100 mg,

excipients:

sucrose – 50 mg;

mineral oil – 80 mg;

propylene glycol – 50 mg;

benzyl alcohol – 27 mg;

water – 693 mg

How to take, the dosage

Externally. Erazaban is recommended to be applied thinly to the affected and adjacent skin areas in adults and children over 12 years of age 5 times a day (about every 3 hours) as soon as possible after the onset of infection.

The average recovery time is 4-6 days.

The cream is applied either with a cotton swab or clean hands to avoid further infection of the affected areas. The effectiveness of the therapy with this product is time-dependent: the earlier in the treatment period from the onset of symptoms, the more effective it is.

Erazaban prevents blistering and crusting if treatment for a recurrent infection begins in the prodromal phase or at the beginning.

The full course of therapy should be carried out for 5 days in order to achieve the greatest effect of the current therapy, even if signs of infection disappear after 1-2 days of treatment. If there is no healing, treatment may be continued for up to 10 days.

Dose adjustment in elderly patients and patients with impaired renal function is not required.

If symptoms persist for more than 10 days, a physician should be consulted.

Interaction

No interaction with other drugs was found during external use.

A strengthening of the effect is noted with the simultaneous administration of immunostimulants.

Special Instructions

The drug Erazaban is for external use only!

Avoid contact of the drug with the eyes, do not apply to the skin near the eyes.

In order to achieve maximum therapeutic effect it is necessary to use the product at the first signs of the disease (burning, itching, tingling, tense sensation and redness).

The product contains propylene glycol and may cause skin irritation. It should not be used on patients who are immunocompromised.

Impact on the ability to drive vehicles, machinery. No effect.

Contraindications

Hypersensitivity to docosanol or any other component of Erazaban; age under 12 years (no experience of use).

With caution: pregnancy and lactation.

Side effects

Headache; dry skin, skin itching, rash, transient redness, soreness, peeling, burning or tingling at the application sites.

These side effects do not usually require withdrawal.

There have been isolated reports of cases of Quincke’s edema with external use of the drug.

If any of the side effects listed worsen, or if the patient notices any other side effects not listed in the descriptions, they should tell their physician.

Overdose

No cases of drug overdose have been reported.

Pregnancy use

Preclinical studies on animals showed no teratogenic embryotoxic effect on the fetus.

Consultation of a physician is required before using Erazaban during pregnancy or while breastfeeding.